NASDAQ:EYEN - Eyenovia Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.05 +0.10 (+1.26 %)
(As of 06/21/2018 08:00 AM ET)
Previous Close$8.05
Today's Range$8.05 - $8.31
52-Week Range$7.32 - $10.74
Volume39,500 shs
Average Volume8,069 shs
Market Capitalization$79.99 million
P/E Ratio-3.68
Dividend YieldN/A
Eyenovia logoEyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio24.96
Quick Ratio24.96


Trailing P/E Ratio-3.68
Forward P/E Ratio-4.30
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book15.78


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares9,940,000

Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.06. View Eyenovia's Earnings History.

What price target have analysts set for EYEN?

2 equities research analysts have issued 1 year price targets for Eyenovia's shares. Their predictions range from $20.00 to $35.00. On average, they anticipate Eyenovia's stock price to reach $27.50 in the next twelve months. View Analyst Ratings for Eyenovia.

Who are some of Eyenovia's key competitors?

Who are Eyenovia's key executives?

Eyenovia's management team includes the folowing people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer, MD & Director (Age 44)
  • Mr. John P. Gandolfo, CFO, Principal Accounting Officer & Sec. (Age 57)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 64)
  • Mr. Luke Clauson, VP of R&D (Age 39)

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

When does Eyenovia's lock-up period expire?

Eyenovia's lock-up period expires on Tuesday, July 24th. Eyenovia had issued 2,730,000 shares in its initial public offering on January 25th. The total size of the offering was $27,300,000 based on an initial share price of $10.00. After the expiration of Eyenovia's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Has Eyenovia been receiving favorable news coverage?

Media headlines about EYEN stock have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyenovia earned a coverage optimism score of 0.03 on Accern's scale. They also gave headlines about the company an impact score of 45.76 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Uniplan Investment Counsel Inc. (3.57%), Millennium Management LLC (2.73%), Highbridge Capital Management LLC (1.51%) and Sabby Management LLC (0.98%). View Institutional Ownership Trends for Eyenovia.

Which major investors are buying Eyenovia stock?

EYEN stock was bought by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Millennium Management LLC, Highbridge Capital Management LLC and Sabby Management LLC. View Insider Buying and Selling for Eyenovia.

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $8.05.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $79.99 million. The company earns $-5,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How can I contact Eyenovia?

Eyenovia's mailing address is 501 Fifth Avenue Suite 1404, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]

MarketBeat Community Rating for Eyenovia (EYEN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.